Results 71 to 80 of about 39,021 (326)

13 Real-world tissue-based circulating tumor DNA (ctDNA) minimal residual disease (MRD) assay predicts outcome in lung cancer patients who had curative treatments [PDF]

, 2022
Youjin Oh, Liam Il‐Young Chung, Soowon Lee, Timothy Hong, Leesul Kim, Sung Mi Yoon, Joo Hee Park, Trie Arni Djunadi, Young Kwang Chae   +8 more
openalex   +1 more source

A subset of MMR‐proficient colon cancers responds to neoadjuvant immunotherapy

Molecular Oncology, EarlyView.
Tan et al. reveal that a distinct subset of early‐stage pMMR colon cancers can respond to neoadjuvant immunotherapy. In the NICHE‐2 trial, responders (26%) were characterized by chromosomal instability, TP53 mutations, and proliferative cell‐cycle programs, whereas nonresponders showed metabolic and stromal reprogramming with TGF‐β‐driven ...
Eleonora Piumatti, Giovanni Germano, Pietro Paolo Vitiello, Alberto Bardelli   +3 more
wiley   +1 more source

Circulating Tumor DNA in Pediatric Cancer

Frontiers in Molecular Biosciences, 2022
The measurement of circulating tumor DNA (ctDNA) has gained increasing prominence as a minimally invasive tool for the detection of cancer-specific markers in plasma.
Louise Doculara, Louise Doculara, Louise Doculara, Toby N. Trahair, Toby N. Trahair, Toby N. Trahair, Narges Bayat, Narges Bayat, Narges Bayat, Richard B. Lock, Richard B. Lock, Richard B. Lock   +11 more
doaj   +1 more source

The evidence base for circulating tumour DNA blood-based biomarkers for the early detection of cancer: a systematic mapping review [PDF]

, 2017
Background: The presence of circulating cell-free DNA from tumours in blood (ctDNA) is of major importance to those interested in early cancer detection, as well as to those wishing to monitor tumour progression or diagnose the presence of activating ...
A Castagnaro, A Melnikov, A Szpechcinski, AM Mazurek, AM Newman, Angela Cox, Anne Reiman, AR Thierry, B Gong, B Taback, Becky L. Whiteman, BH Kim, C Bettegowda, C Chiappetta, C Kneip, CF Eisenberger, CH Metz, CP Lange, D Hanahan, D Madhavan, Dawn Teare, DM Hyman, DM Kurtz, E Cassinotti, E Crowley, E Danese, E Heitzer, E Heitzer, E Kirkizlar, E Papadopoulou, E Zonta, ER Zaher, EY Rykova, F Andriani, F Diehl, F Perrone, F Salvianti, F Tian, G Huang, G Sharma, G Sozzi, G Weiss, Helen Buckley Woods, HS Hsu, Hugh Kikuchi, I Andolfo, I Ibanez de Caceres, I Skrypkina, IA Cree, IA Cree, Ian A. Cree, J Belic, J Ellinger, J Martinez-Galan, J Melson, J Tabernero, J Uchida, Jacqui Shaw, JD Warren, JM Yi, JY Wang, K Page, K Page, K Sikora, K Toth, K Warton, KL Aung, KL Spindler, L Benesova, L Chen, L De Mattos-Arruda, L Fernandez-Cuesta, L Sorber, L Uttley, Lesley Uttley, LS Kristensen, M Agostini, M Chimonidou, M Chimonidou, M de Martino, M Seefeld, M Shan, M Zane, MB Freidin, Michael Messenger, MJ Duffy, MO Hoque, NA Mohamed, NT Potter, Orla Sheils, P Jin, P Xia, PJ Johnson, PM Bossuyt, Q Zhang, QT Zhao, R Divella, R Dumache, R Grutzmann, R Mead, R Minciu, R Radpour, RA Zanetti-Dallenbach, RF Andersen, S Begum, S Couraud, S Hauser, S Kurihara, S McPhail, S Salvi, SC Pack, Sian Taylor Philips, SK Kadam, SR Payne, Susan Harnan, T deVos, T Powrozek, T Powrozek, TB Hao, TE Skvortsova, TR Church, U Ladabaum, V Kloten, V Swarup, X Lou, X Shao, XY Zhong, Y Zhang, YB Kuo, YJ Yang, YJ Zhang, YM Lo, YM Lo, YM Lo   +133 more
core   +3 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Advances in Clinical Application of ctDNA in Tumor Detection, Screening, Prognosis and Treatment

Zhongliu Fangzhi Yanjiu, 2020
Circulating tumor DNA (ctDNA) is a tumor-derived fragmented DNA in blood and is a characteristic marker of tumor. Through the correlative detection of ctDNA, the trace information of the tumor in the blood of the patients can be detected, and the ...
LIU Yong
doaj   +1 more source

Circulating tumor DNA predicts survival in patients with resected high risk stage II/III melanoma [PDF]

, 2017
Background: Patients with high-risk stage II/III resected melanoma commonly develop distant metastases. At present, we cannot differentiate between patients who will recur or those who are cured by surgery.
Corrie, P. G., Dhomen, N., Dunn, Janet A., Fisher, N., Gremel, G., Lee, R. J., Lorigan, P., Marais, R., Marshall, A. (Andrea)‏, Middleton, M. R., Myers, K. A.   +10 more
core   +1 more source

Red Blood Cells Internalize Extracellular DNA via Apoptotic Bodies with Clinical Relevance to Cancer Patients

Advanced Science, EarlyView.
Mature red blood cells (RBCs) can capture extracellular DNA, with short fragments homologous to cfDNA. This uptake is mediated by apoptotic bodies, which induce RBC oxidative stress, deformation, and accelerated in vivo clearance. The rbcDNA abundance correlates with tumor burden and therapeutic response, highlighting its potential as a liquid biopsy ...
Zihang Zeng, Zongbi Yi, Jing Hu, Jiali Li, Yu Xu, Xiuli Guo, Qian Ji, Kaixiang Feng, Ying Zhang, Sirui Bai, Yushuang Tan, Yufei Yan, Linzhi Han, Jing Jiang, Tengfei Wang, Xiang Wang, Ziqing Zhan, Ruiying Huang, Jinfang Zhang, Conghua Xie, Binghe Xu   +20 more
wiley   +1 more source

A headlight on liquid biopsies: a challenging tool for breast cancer management [PDF]

, 2016
Breast cancer is the most frequent carcinoma and second most common cause of cancer-related mortality in postmenopausal women. The acquisition of somatic mutations represents the main mechanism through which cancer cells overcome physiological cellular ...
Barraco, Nadia, BAZAN, Viviana, BRONTE, Giuseppe, CALO', Valentina, Cangemi, Antonina, CASTIGLIA, Marta, CICERO, Giuseppe, DI PIAZZA, Florinda, FANALE, Daniele, Massihnia, Daniela, PANTUSO, Gianni, Perez, Alessandro, RIZZO, Sergio, RUSSO, Antonio   +13 more
core   +1 more source

Targeting WEE1 in ARID1A/TP53 Concurrent Mutant Colorectal Cancer by Exploiting R‐Loop Accumulation and DNA Repair Deficiencies

Advanced Science, EarlyView.
ARID1A, a SWI/SNF complex component, is frequently mutated in colorectal cancer (CRC). CRC with ARID1A/TP53 concurrent mutations shows marked sensitivity to WEE1 inhibition. ARID1A loss induces R‐loop‐mediated replication stress, impairs ATF3 transcription, and amplifies WEE1i‐induced DNA damage, suggesting a promising therapeutic vulnerability ...
Chi Zhang, Yanjing Zhu, Luoyan Ai, Jingyuan Wang, Shan Yu, Yichen Wang, Xiaojing Xu, Mengling Liu, Yiyi Yu, Mengxuan Zhu, Yutong Liu, Zhenghang Xu, Haojie Zhou, Huishan Li, Qihong Huang, Qing Liu, Ke Peng, Tianshu Liu   +17 more
wiley   +1 more source